SENORES PHARMACEUTICALS L (SENORES) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of SENORES PHARMACEUTICALS L stock ₹380, price ₹1,148, that is 66.9% below the price, quality 44 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
SENORES PHARMACEUTICALS L
SENORES · NSEFar too expensive (fair value 67% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
23‑month range ₹444.30 – ₹1,551 · fair‑value band ₹271.52 – ₹488.95 · the ₹1,148 price screens above the ₹380.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether SENORES PHARMACEUTICALS L is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally.
Show moreShow less
It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services.
The company was incorporated in 2017 and is based in Ahmedabad, India.
Stock analysis
SENORES PHARMACEUTICALS L (SENORES) currently trades at ₹1,148, while our model-based Fair Value estimate is ₹380.21, 67% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹1,164 per share, and 2 of the 14 models we run sit above the ₹1,148 price.
Bear case: the Economic Profit group reads lowest at ₹151.23, and 12 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹271.52 (bear) to ₹488.95 (bull), the price of ₹1,148 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SENORES PHARMACEUTICALS L reported revenue of ₹6.3B in FY2026 versus ₹141M in FY2022, a compound +159.0%/yr. Reported net income was ₹1.2B in FY2026, compounding +228.5%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap ₹50.2B (≈ $533M) Small · P/E ratio 37.7 · P/S ratio 7.55 · EPS (TTM) ₹30.45 · Net margin 18.7% · Return on equity 13.8% · Return on assets (EBIT) 105% (5-year average) · Operating margin 24.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 62% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −67%, SENORES screens richer than that median.
Fair Value models
All 14 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
SENORES screens overvalued: fair value 67% below the price. Compare with Eli Lilly and Company →
Compare SENORES PHARMACEUTICALS L with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Bristol-Myers Squibb Company BMY | $63.43 | $75.91 | +20% | vs SENORES |
| Amgen Inc AMGN | $465.67 | $512.24 | +10% | vs SENORES |
| Gilead Sciences, Inc GILD | $168.08 | $184.89 | +10% | vs SENORES |
| Novartis AG NOVN | CHF 134.06 | CHF 122.91 | −8% | vs SENORES |
| AbbVie Inc ABBV | $295.03 | $259.62 | −12% | vs SENORES |
| Merck & Co MRK | $147.76 | $129.26 | −13% | vs SENORES |
| Pfizer Inc PFE | $28.89 | $24.87 | −14% | vs SENORES |
| Roche Holding RO | CHF 412.00 | CHF 326.56 | −21% | vs SENORES |
| Johnson & Johnson, JNJ | $285.75 | $169.03 | −41% | vs SENORES |
| Eli Lilly and Company LLY | $1,444 | $749.92 | −48% | vs SENORES |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is SENORES PHARMACEUTICALS L (SENORES) overvalued or undervalued?
What is the fair value of SENORES?
What is the quality score of SENORES?
What is the price target for SENORES PHARMACEUTICALS L (SENORES)?
What is the SENORES PHARMACEUTICALS L stock forecast for 2026?
What is the revenue of SENORES PHARMACEUTICALS L (SENORES)?
What is the intrinsic value of SENORES PHARMACEUTICALS L (SENORES)?
Is SENORES PHARMACEUTICALS L stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SENORES?
How much is SENORES PHARMACEUTICALS L worth?
What do the bullish and bearish scenarios say about SENORES?
What is the P/E ratio of SENORES?
How solid is the balance sheet of SENORES PHARMACEUTICALS L (SENORES)?
How far is SENORES from its 52-week high?
Which stocks are comparable to SENORES PHARMACEUTICALS L?
Is SENORES PHARMACEUTICALS L stock attractive at the current price?
How is the fair value of SENORES calculated?
Is it still worth investing in stocks now?
What is the share price of SENORES PHARMACEUTICALS L (SENORES)?
What should I pay attention to with SENORES PHARMACEUTICALS L right now?
Key figures of SENORES PHARMACEUTICALS L
How large is the market capitalisation of SENORES PHARMACEUTICALS L (SENORES)?
What is the P/S ratio of SENORES PHARMACEUTICALS L (SENORES)?
What are the earnings per share of SENORES PHARMACEUTICALS L (SENORES)?
What is the net margin of SENORES PHARMACEUTICALS L (SENORES)?
What is the return on equity of SENORES PHARMACEUTICALS L (SENORES)?
What is the EBIT return on assets of SENORES PHARMACEUTICALS L (SENORES)?
What is the operating margin of SENORES PHARMACEUTICALS L (SENORES)?
How fast is revenue growing at SENORES PHARMACEUTICALS L (SENORES)?
How fast are earnings growing at SENORES PHARMACEUTICALS L (SENORES)?
How much free cash flow does SENORES PHARMACEUTICALS L (SENORES) generate?
How much net debt does SENORES PHARMACEUTICALS L (SENORES) carry?
Watch SENORES PHARMACEUTICALS L in the live analysis
One click puts SENORES PHARMACEUTICALS L on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.